Cellect secures stem cell-based therapy patent

By The Science Advisory Board staff writers

August 6, 2020 -- Cellect Biotechnology has secured a European patent for its stem cell selection technology. The patent was also approved in Australia and Israel, according to the firm.

European patent No. 14851547.1 will expire in October 2034. It covers the regenerative capacity of stem and progenitor cells in the company's Apograft cell-based blood product. Importantly, it protects the intellectual property of the second component of Apograft involving the activation of stem and progenitor cells.

Cellect currently holds 45 patents, it said.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.